Drug intelligence / Profile preview

Pfs25 VLP-FhCMB + Alhydrogel

Development stage: Phase 1
Lead developer: Fraunhofer USA Center for Molecular Biotechnology
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Pfs25 VLP-FhCMB + Alhydrogel** is an investigational malaria transmission-blocking vaccine. It consists of virus-like particles (VLPs) containing the recombinant *Plasmodium falciparum* Pfs25 antigen fused to Alfalfa mosaic virus coat protein, produced in *Nicotiana benthamiana* plants using a recombinant vector. The Pfs25 component targets sexual-stage parasites (gametes, zygotes, ookinetes) within the mosquito midgut to prevent transmission. Formulated with the aluminum hydroxide-based adjuvant Alhydrogel, the vaccine induces anti-Pfs25 antibodies that inhibit *P. falciparum* development in mosquitoes. It is developed for intramuscular administration and is under evaluation for safety and immunogenicity in humans as a transmission-blocking strategy[1][3][5][7].

Brand names: Pfs25 VLP-FhCMB + Alhydrogel
Other names: Plant-produced Pfs25 virus-like particle malaria vaccine + AlhydrogelPfs25-CP VLP + AlhydrogelMalaria transmission-blocking vaccine (Pfs25 VLP + Alhydrogel)

Targets

Pfs25

Beyond the preview

Go deeper on Pfs25 VLP-FhCMB + Alhydrogel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pfs25 VLP-FhCMB + Alhydrogel.

Explore the full profile